Goldman Sachs initiated coverage on Atara Biotherapeutics (NASDAQ: ATRA) with a Neutral rating and a price target of $30.00.Analyst Navdeep ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View New Coverage

Atara Biotherapeutics (ATRA) Reports Q3 Loss of $4.20November 12, 2014 6:36 AM Jefferies Starts Atara Biotherapeutics (ATRA) at BuyNovember 10, 2014 7:13 AM